Advertisement

Re:Cognition Health Establishes Ireland's Premier Alzheimer's Disease-Modifying Treatment Clinic

48.6K
486
160
Re:Cognition Health Establishes Ireland's Premier Alzheimer's Disease-Modifying Treatment Clinic
Re:Cognition Health, a leading independent provider of advanced Alzheimer's treatments, has opened its first clinic in Ireland, situated in Dublin. This new facility represents a significant advancement in the landscape of dementia care for the region.

Revolutionizing Alzheimer's Care: A New Era for Ireland

Ireland's First Dedicated Alzheimer's Treatment Center Opens

The newly established clinic, located at Tallaght Cross East, Dublin, is set to become Ireland's premier independent memory center. It will provide patients with early-stage Alzheimer's disease access to cutting-edge therapies such as Leqembi® (lecanemab) and Kisunla® (donanemab).

Breakthrough Therapies Offer New Hope

The launch of this clinic follows the regulatory approval of both Leqembi and Kisunla in Ireland. These therapies represent a transformative shift in Alzheimer's treatment, moving beyond symptom management to address the core biological mechanisms of the disease. As anti-amyloid monoclonal antibodies, they work to clear toxic amyloid proteins from the brain, which are a hallmark of Alzheimer's. Clinical studies have demonstrated their ability to slow the progression of the disease in individuals with early and accurately diagnosed Alzheimer's.

Meeting a Critical Unmet Need

Previously, many Irish patients seeking these innovative treatments had to travel to Re:Cognition Health's clinics in the UK for specialized assessment, diagnostic procedures, and ongoing care. The substantial demand from Irish patients and their families underscored a critical need for accessible, specialist memory services within Ireland. This new clinic directly addresses that need, providing world-class treatment closer to home.

Future Expansion and Commitment to Irish Healthcare

This Dublin clinic is the initial step in Re:Cognition Health's broader expansion strategy in Ireland. The organization plans to introduce additional memory services and specialized clinics as the demand for advanced dementia care continues to grow across the country. This commitment ensures that more patients will benefit from cutting-edge diagnostics and treatment options.

Transformative Impact on Patient Lives

Professor Sean Kennelly, Clinical Director for Ireland at Re:Cognition Health, emphasizes the profound impact of disease-modifying therapies. He notes that these treatments allow for interventions that tackle the root causes of Alzheimer's, rather than just managing its symptoms. This development liberates Irish families from the logistical and financial burdens of seeking treatment abroad, offering them local access to expert care and support.

A Landmark Achievement for Dementia Care

Dr. Emer MacSweeney, CEO, Co-Founder, and Medical Director of Re:Cognition Health, highlights the clinic's significance as a landmark moment for dementia care in Ireland. She states that the approval and delivery of these therapies have permanently altered the treatment landscape. Drawing on extensive experience from pivotal clinical trials and routine practice in the UK, Re:Cognition Health's team of cognitive experts understands both the scientific intricacies and the patient journey. The Dublin opening is a logical progression, aimed at ensuring comprehensive access to world-class diagnosis, treatment, and ongoing specialist care, enabling eligible patients to maintain a better quality of life for longer.

Empowering Patients Through Early Intervention

The establishment of this clinic underscores the increasing understanding that early and accurate diagnosis is paramount for patients to benefit from therapies that can slow disease progression. As disease-modifying treatments become more widespread, timely assessment and biomarker-driven diagnostics are becoming indispensable components of modern dementia care. Re:Cognition Health's new facility in Dublin reinforces its international leadership in early diagnosis, Alzheimer's clinical research, and the provision of disease-modifying treatments, extending its commitment to innovative dementia care throughout Europe.

Advertisement